SCHEMBL307289

SCHEMBL307289

CC(C(N)=O)C(=O)Nc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
ALDH1A1 P00352 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
RXFP1 Q9HBX9 1/20 0.58
TAAR1 Q96RJ0 1/20 0.54
POLB P06746 2/20 0.53
GAA P10253 3/20 0.53
LMNA P02545 1/20 0.53
ATM Q13315 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
HPGD P15428 2/20 0.50
HTT P42858 2/20 0.50
RAB9A P51151 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSP90AA1 P07900 1/20 0.50
GPR55 Q9Y2T6 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MME P08473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18852431 0.88 ALDH1A1 (0.66) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL306653 0.84 MAPT (0.67) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL19822858 0.83 MAPT (0.56) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL14817491 0.82 ALDH1A1 (0.59) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL4668132 0.82 ALDH1A1 (0.65) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL4593022 0.81 MAPT (0.54) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL14580288 0.81 ALDH1A1 (0.62) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL10787070 0.80 POLB (0.57) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL5960486 0.80 TAAR1 (0.79) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL4741417 0.80 TAAR1 (0.79) MAPTALDH1A1MEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957498-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING MethylGene Inc. (CA) 2008-08-20 EP claimed
WO-2008041053-A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE, INC. (CA) 2008-04-10 WO claimed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US claimed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY Mirati Therapeutics, Inc. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 MAPT 1502/4885ALDH1A1 784/4885MEN1 1043/4885
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 MAPT 2430/4885ALDH1A1 1649/4885MEN1 3655/4885
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET MAPT 1806/4885ALDH1A1 3139/4885MEN1 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.